🇺🇸 FDA
Pipeline program

Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

CNTO1959PSA3004

Phase 3 small_molecule active

Quick answer

Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL for Psoriatic arthritis (PsA) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Psoriatic arthritis (PsA)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials